Towards an In Silico Approach to Personalized Pharmacokinetics

The human genome sequence project has made a great impact on medical science and drug discovery (Collins et al., 2003). The rapid progress of genome sequencing technologies enables us to study personal genome sequences with reasonable costs (Mitchelson, 2007). It is now widely believed that personal genome information will be one of the most important biomedical contributions to personalized medicine, that is, medical and health care based on individual genetics (Angrist, 2007). Personalized medicine has opened the doors to new and emerging technologies in genome drug discovery, including pharmacogenetics, pharmacokinetics, and pharmacodynamics, to name but a few. Pharmacogenetics investigates genetic effects in drug metabolic enzymes and drug transporters for drug efficacy (Pirmohamed, 2011). Pharmacokinetics and dynamics (PKPD) focus on the area under plasma concentration time curve (AUC) of drugs, one of the important indices to check the drug effects in the human body, especially for preventing adverse side effects (Gabrielsson et al., 2009).

[1]  R. N. Brogden,et al.  Ketoconazole: A Review of its Therapeutic Efficacy in Superficial and Systemic Fungal Infections , 2012, Drugs.

[2]  Ryuzo Azuma,et al.  Discovering Dynamic Characteristics of Biochemical Pathways using Geometric Patterns among Parameter-Parameter Dependencies in Differential Equations , 2007, New Generation Computing.

[3]  Daniel P. Miranker,et al.  Mapping between the OBO and OWL ontology languages , 2011, J. Biomed. Semant..

[4]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[5]  Jenny Y Chien,et al.  STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE , 2006, Drug Metabolism and Disposition.

[6]  José L. V. Mejino,et al.  A reference ontology for biomedical informatics: the Foundational Model of Anatomy , 2003, J. Biomed. Informatics.

[7]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[8]  H. Okuda,et al.  A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[10]  Akihiko Konagaya,et al.  Trends in life science grid: from computing grid to knowledge grid , 2006, BMC Bioinformatics.

[11]  Yuichi Sugiyama,et al.  A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU , 2001, Pharmaceutical Research.

[12]  Akihiko Konagaya,et al.  Cluster newton method for sampling multiple solutions of an underdetermined inverse problem: Parameter identification for pharmacokinetics , 2011 .

[13]  Akihiko Konagaya.  OBIGrid: towards the 'Ba' for sharing resources, services and knowledge for bioinformatics , 2006 .

[14]  M. Pirmohamed.  Pharmacogenetics: past, present and future. , 2011, Drug discovery today.

[15]  K. Mitchelson,et al.  New high throughput technologies for DNA sequencing and genomics , 2007 .

[16]  Stefan Willmann,et al.  Theoretical Biology and Medical Modelling Open Access Dynamically Simulating the Interaction of Midazolam and the Cyp3a4 Inhibitor Itraconazole Using Individual Coupled Whole-body Physiologically-based Pharmacokinetic (wb-pbpk) Models , 2022 .

[17]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Barry Smith,et al.  Biodynamic ontology: applying BFO in the biomedical domain. , 2004, Studies in health technology and informatics.

[19]  Werner Ceusters,et al.  A Unified Framework for Biomedical Terminologies and Ontologies , 2010, MedInfo.

[20]  Soma Das,et al.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Hugues Dolgos,et al.  Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.

[22]  Ron H J Mathijssen,et al.  Modulation of irinotecan metabolism by ketoconazole. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Kazuo Komamura,et al.  UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer , 2004, Clinical pharmacology and therapeutics.

[25]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[26]  Olivier Bodenreider,et al.  Experience in Reasoning with the Foundational Model of Anatomy in OWL DL , 2005, Pacific Symposium on Biocomputing.

[27]  Ryuzo Azuma,et al.  Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation , 2008, BMC Bioinformatics.

[28]  Kei-Hoi Cheung,et al.  Semantic Web: Revolutionizing Knowledge Discovery in the Life Sciences , 2006 .

[29]  Olivier Bodenreider,et al.  The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..

[30]  James A. Hendler,et al.  Scientific publishing on the 'semantic web' , 2001 .

[31]  Sumi Yoshikawa,et al.  Drug Interaction Ontology (DIO) for Inferences of Possible Drug-drug Interactions , 2004, MedInfo.

[32]  R. Tukey,et al.  Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. , 2002, Molecular pharmacology.

[33]  Barry Smith,et al.  SNAP and SPAN: Towards Dynamic Spatial Ontology , 2004, Spatial Cogn. Comput..

[34]  J. Zamecnik,et al.  Mouse hepatic metabolites of ketoconazole: isolation and structure elucidation. , 1994, Journal of pharmaceutical and biomedical analysis.